Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Molecular basis to diet-dependent chromatin dependencies in prostate cancer

FY 2019-20

Summary
"Prostate cancer is a heterogeneous disease and the genetic basis for this interpatient heterogeneity remains unclear. The overtreatment of indolent prostate cancers, which causes unnecessary treatment toxicity, and the ongoing development of new therapies for aggressive prostate cancers increases the need for accurate patient classification and stratification. Systemic metabolic alterations associated with increased intake of saturated fat and obesity are linked with higher risk of prostate cancer progression and mortality. Epigenetic alterations are frequently observed in prostate cancer, yet how aberrant epigenetic signatures are established is poorly understood. We hypothesize that epigenetic reprogramming underlies prostate cancer aggressiveness. Recent data from our laboratory suggest that prostate cancer harbour altered chromatin accessibility in response to a high-fat diet and a potential epigenetic mediator of this phenotype has been identified. Our first aim is to determine, using genome editing techniques, if this candidate gene is a driver of high-fat diet-dependent prostate cancer aggressiveness using cellular and mouse models. Moreover, we have recently identified epigenetic modifications specific to aggressive prostate tumours. Thus, our second aim is to determine if these epigenetic alterations are drivers of aggressive prostate cancer using genome editing and multiple sequencing technologies in various models. Altogether, by elucidating the underlying cause to prostate cancer metastatic progression, our research project will lead to new methods and clinical tests to group patients into high and low-risk groups and the development of new treatments to significantly extend the life of prostate cancer patients."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428921
Name
Larocque Janie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Molecular basis to diet-dependent chromatin dependencies in prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ataq-Seq; Cancer Biology; Chip-Seq; Chromatin; Crispr/Cas9 Editing; Diet; Epigenetics; Mouse Models; Prostate Cancer; Rna-Seq
Abstract
"Prostate cancer is a heterogeneous disease and the genetic basis for this interpatient heterogeneity remains unclear. The overtreatment of indolent prostate cancers, which causes unnecessary treatment toxicity, and the ongoing development of new therapies for aggressive prostate cancers increases the need for accurate patient classification and stratification. Systemic metabolic alterations associated with increased intake of saturated fat and obesity are linked with higher risk of prostate cancer progression and mortality. Epigenetic alterations are frequently observed in prostate cancer, yet how aberrant epigenetic signatures are established is poorly understood. We hypothesize that epigenetic reprogramming underlies prostate cancer aggressiveness. Recent data from our laboratory suggest that prostate cancer harbour altered chromatin accessibility in response to a high-fat diet and a potential epigenetic mediator of this phenotype has been identified. Our first aim is to determine, using genome editing techniques, if this candidate gene is a driver of high-fat diet-dependent prostate cancer aggressiveness using cellular and mouse models. Moreover, we have recently identified epigenetic modifications specific to aggressive prostate tumours. Thus, our second aim is to determine if these epigenetic alterations are drivers of aggressive prostate cancer using genome editing and multiple sequencing technologies in various models. Altogether, by elucidating the underlying cause to prostate cancer metastatic progression, our research project will lead to new methods and clinical tests to group patients into high and low-risk groups and the development of new treatments to significantly extend the life of prostate cancer patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Larocque, Janie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~